Viatris ROE 2010-2025 | VTRS

Current and historical return on equity (ROE) values for Viatris (VTRS) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Viatris ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2025-03-31 $-3.79B $15.65B -20.60%
2024-12-31 $-0.63B $18.64B -3.25%
2024-09-30 $-0.88B $19.79B -4.43%
2024-06-30 $-0.65B $19.52B -3.20%
2024-03-31 $-0.06B $20.01B -0.27%
2023-12-31 $0.05B $20.47B 0.26%
2023-09-30 $1.83B $20.87B 8.75%
2023-06-30 $1.85B $20.84B 9.04%
2023-03-31 $1.90B $20.93B 9.40%
2022-12-31 $2.08B $21.07B 10.32%
2022-09-30 $0.80B $19.18B 4.02%
2022-06-30 $0.76B $19.81B 3.72%
2022-03-31 $0.17B $20.45B 0.81%
2021-12-31 $-1.27B $20.49B -6.02%
2021-09-30 $-1.92B $21.14B -8.86%
2021-06-30 $-2.05B $21.21B -10.48%
2021-03-31 $-1.73B $21.42B -10.07%
2020-12-31 $-0.67B $22.95B -4.58%
2020-09-30 $0.27B $12.55B 2.25%
2020-06-30 $0.27B $11.75B 2.34%
2020-03-31 $0.06B $11.26B 0.54%
2019-12-31 $0.02B $11.88B 0.14%
2019-09-30 $0.05B $11.46B 0.40%
2019-06-30 $0.03B $11.90B 0.28%
2019-03-31 $0.24B $11.89B 1.99%
2018-12-31 $0.35B $12.17B 2.85%
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
Sector Industry Market Cap Revenue
Medical Medical Services $10.281B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $140.565B 26.36
Elevance Health (ELV) United States $91.235B 11.77
CVS Health (CVS) United States $79.418B 9.87
Cencora (COR) United States $56.719B 19.73
DiDi Global (DIDIY) China $21.932B 33.29
Natera (NTRA) United States $20.928B 0.00
BioMerieux (BMXMF) France $15.355B 0.00
Solventum (SOLV) United States $13.109B 13.88
EUROFINS SCIENT (ERFSF) Luxembourg $11.943B 0.00
CochLear (CHEOY) Australia $11.734B 0.00
Revvity (RVTY) United States $11.115B 19.13
ICON (ICLR) Ireland $10.559B 9.82
Doximity (DOCS) United States $10.038B 46.76
Avantor (AVTR) United States $9.104B 13.23
Medpace Holdings (MEDP) United States $8.794B 23.36
HealthEquity (HQY) United States $8.442B 41.53
Sonic Healthcare (SKHHY) Australia $8.311B 0.00
Charles River Laboratories (CRL) United States $6.944B 13.61
Amplifon S.p.A (AMFPF) Italy $4.966B 26.21
BrightSpring Health Services (BTSG) United States $4.201B 38.89
Bausch + Lomb (BLCO) Canada $4.160B 24.52
Sotera Health (SHC) United States $3.616B 20.55
Alignment Healthcare (ALHC) United States $3.213B 0.00
Surgery Partners (SGRY) United States $3.025B 39.33
Concentras Parent (CON) United States $2.892B 16.71
Organon (OGN) United States $2.340B 2.49
Ardent Health Partners (ARDT) United States $2.167B 9.24
GeneDx Holdings (WGS) United States $2.026B 78.04
Premier (PINC) United States $1.903B 14.44
Progyny (PGNY) United States $1.843B 40.57
PACS (PACS) United States $1.623B 0.00
GoodRx Holdings (GDRX) United States $1.411B 28.21
Teladoc Health (TDOC) United States $1.282B 0.00
Pediatrix Medical (MD) United States $1.277B 9.72
Establishment Labs Holdings (ESTA) $1.065B 0.00
Ryman Healthcare (RYHTY) New Zealand $0.998B 0.00
CareDx (CDNA) United States $0.986B 15.39
Nutex Health (NUTX) United States $0.981B 14.82
Agilon Health (AGL) United States $0.969B 0.00
AMN Healthcare Services Inc (AMN) United States $0.858B 8.04
QDM (QDMI) Hong Kong, SAR China $0.729B 0.00
Embecta (EMBC) United States $0.679B 4.57
InnovAge Holding (INNV) United States $0.566B 0.00
Enhabit (EHAB) United States $0.539B 44.38
Auna S.A (AUNA) Luxembourg $0.524B 13.88
Sonida Senior Living (SNDA) United States $0.494B 0.00
LifeMD (LFMD) United States $0.481B 0.00
COMPASS Pathways (CMPS) United Kingdom $0.404B 0.00
SBC Medicals (SBC) United States $0.353B 0.00
Oncology Institute (TOI) United States $0.231B 0.00
Performant Healthcare (PHLT) United States $0.211B 0.00
Beauty Health (SKIN) United States $0.205B 0.00
DocGo (DCGO) United States $0.148B 24.17
Sera Prognostics (SERA) United States $0.087B 0.00
So-Young (SY) China $0.087B 0.00
KindlyMD (KDLY) United States $0.084B 0.00
OncoCyte (OCX) United States $0.080B 0.00
Ascend Wellness Holdings (AAWH) United States $0.063B 0.00
NeueHealth (NEUE) United States $0.061B 0.00
IceCure Medical (ICCM) Israel $0.057B 0.00
Biodesix (BDSX) United States $0.044B 0.00
Basel Medical Group (BMGL) Singapore $0.039B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.033B 0.00
Pheton Holdings (PTHL) China $0.032B 0.00
SeaStar Medical Holding (ICU) United States $0.013B 0.00
ModivCare (MODV) United States $0.013B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
Intelligent Bio Solutions (INBS) United States $0.009B 0.00
XWELL (XWEL) United States $0.005B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.002B 0.00
NewGenIvf Group (NIVF) Thailand $0.002B 0.00
Cano Health (CANOQ) United States $0.000B 0.00